-
FDA grants IND clearance for Servier’s UCART19 to treat relapsed / refractory ALL
pharmaceutical-technology
March 14, 2017
The US Food and Drug Administration (FDA) has granted an investigational new drug (IND) clearance to Servier to ...
-
Trump's FDA pick Gottlieb calls vaccine, autism theories 'thoroughly debunked'
fiercepharma
March 14, 2017
Those who counted President Donald Trump an ally against vaccines might be disappointed to hear what his pick to head up the FDA has said on the subject.
-
Former FDA deputy commissioner Scott Gottlieb heads Trump's picks to lead agency: sources
firstwordpharma
March 13, 2017
According to people familiar with the matter, former FDA deputy commissioner Scott Gottlieb is the top choice of US President Donald Trump to lead the agency, several news outlets reported Friday.
-
FDA Grants Orphan Drug Designation to Boehringer Ingelheim's Investigational Anti-CD33 Monoclonal An
americanpharmaceuticalreview
March 13, 2017
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its anti-CD33 monoclonal antibody BI 836858 for the treatment of myelodysplastic syndromes (MDS).
-
FDA accepts sNDA for Vraylar
cphi-online
March 10, 2017
Application seeks to expand Vraylar label to include Phase III clinical data for the maintenance treatment of schizophrenia.
-
13 FDA observations on Dr Reddy's plant send shares to 3 year low
pharmafile
March 10, 2017
Indian pharmaceutical firm Dr Reddy’s has seen its shares drop on the Bombay Stock Exchange to ...
-
FDA Grants Orphan Drug Designation to CSRA’s DynPort Vaccine Company for Plague Vaccine
firstwordpharma
March 09, 2017
DynPort's clinical stage recombinant Yersinia pestis rF1V plague vaccine to benefit from FDA Orphan Drug Designation
-
FDA Accepts sBLA Filing of Soliris® as a Potential Treatment for Patients with Refractory Generalize
americanpharmaceuticalreview
March 09, 2017
Alexion Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental Biologics License Application (sBLA) to extend the indication for Soliris® (eculizumab) as a potential treatment for
-
FDA and NICE approve of first new hyperparathyroidism drug in 12 years
pharmafile
March 09, 2017
The FDA has given the go-ahead for Amgen’s hyperparathyroidism (HPT) therapy Parsabiv (etelcalcetide), marking the...
-
Teligent, Receives FDA Approval of Clobetasol Propionate Gel, 0.05%
americanpharmaceuticalreview
March 09, 2017
Teligent, a New Jersey-based specialty generic pharmaceutical company, has received approval of the company's abbreviated new drug application (ANDA) from the U.S.